ELCC 2023 | Amivantamab in patients with EGFR Ex20ins-mutated NSCLC

Pilar Garrido Lopez, MD, PhD, University Hospital Ramón y Cajal, Madrid, Spain, comments on the data relating to the use of amivantamab as monotherapy in patients with EGFR exon 20 insertion (Ex20ins)-mutated NSCLC. Long-term follow-up data was obtained following the Phase I CHRYSALIS (NCT02609776) study, in which patients with Ex20ins-mutated NSCLC were a subgroup. Patients had previously received platinum-based chemotherapy treatment, and following amivantamab monotherapy a median overall survival (OS) of over 20 months, and a 47% 2-year OS rate, was noted. Toxicities were manageable, and from this stage, further investigation of the biomarkers present in patients who received long-term therapy should be undertaken. This interview took place at the European Lung Cancer Congress 2023 in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.